<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137188</url>
  </required_header>
  <id_info>
    <org_study_id>H-2-2010-001</org_study_id>
    <nct_id>NCT01137188</nct_id>
  </id_info>
  <brief_title>Effect of Weight Loss on Psoriasis</brief_title>
  <official_title>Effect of Weight Loss on Skin Manifestations, Inflammatory Markers and Risk Factor for Comorbidity in Obese Patients With Psoriasis - a Randomized Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Controlled data show that obesity is a risk factor for psoriasis and that psoriasis severity
      is correlated with the degree of overweight. No controlled interventional studies reporting
      on the effect of weight loss on psoriatic skin manifestations have been published and data
      from case reports are conflicting.

      Patients with psoriasis demonstrate an increased susceptibility to atherosclerotic
      comorbidities such as arterial hypertension, coronary vascular disease, stroke,
      hyperlipidemia and type II diabetes and in severe psoriasis there is an increased risk of
      early death. Lately the role of inflammation in the atherosclerotic process has been
      highlighted and the link between psoriasis and atherosclerosis may be explained by the
      concomitant systemic inflammation in psoriasis. Similarly a state of low level inflammation
      is seen in obesity where macrophages and adipocytes begin to show overlap in function and
      gene expression. This leads to an increased migration of macrophages into the adipose tissue
      and an increased secretion of pro-inflammatory cytokines. In summary, these data and
      theoretical considerations suggest that weight loss in obese patients with psoriasis may
      improve skin manifestations and reduce the risk of atherosclerotic comorbidity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI</measure>
    <time_frame>Baseline</time_frame>
    <description>Psoriasis area and severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PASI</measure>
    <time_frame>4 weeks</time_frame>
    <description>Psoriasis area severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PASI</measure>
    <time_frame>8 weeks</time_frame>
    <description>Psoriasis area severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PASI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Psoriasis area severity index</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PASI</measure>
    <time_frame>16 weeks</time_frame>
    <description>Psoriasis area severity index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for comorbidity</measure>
    <time_frame>Baseline</time_frame>
    <description>Risk factors for comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for comorbidity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Risk factors for comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for comorbidity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Risk factors for comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for comorbidity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Risk factors for comorbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for comorbidity</measure>
    <time_frame>16 weeks</time_frame>
    <description>Risk factors for comorbidity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive weight loss program and regular group sessions with clinical dietician. Complete dietary substitution with a low calorie diet containing 800-1000 kcal/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Study subjects will receive routine dietary counseling for 8 weeks and will cross over to intervention upon completion</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low calorie diet</intervention_name>
    <description>Low calorie diet containing 800-1000 kcal/day</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate/severe psoriasis at inclusion or previous to systemic immunosuppressive
             therapy

          -  BMI &gt; 27

        Exclusion Criteria:

          -  pregnancy/breast feeding

          -  diabetes requiring insulin treatment

          -  severe heart/kidney/liver disease

          -  gout

          -  high potassium intake

          -  obesity due to medical conditions/medications

          -  use of medical treatment for obesity

          -  previous bariatric surgery

          -  intentional/unintentional weight loss up to 3 months prior to inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lone Skov, MD, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen University Hospital Gentofte, Department of Dermato-venerology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen University Hospital Gentofte, Department of Dermato-venerology</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>April 3, 2012</last_update_submitted>
  <last_update_submitted_qc>April 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Jensen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

